vincristine + asparaginase + dexamethasone + cytarabine + methotrexate

Vincristine + asparaginase + dexamethasone + cytarabine + methotrexate is a multi-agent chemotherapy induction regimen used for the treatment of newly diagnosed standard-risk acute lymphoblastic leukemia (ALL) in pediatric patients (ages 1–10). This combination serves as the induction backbone in the Phase 2 NCT06099366 trial, which utilizes next-generation sequencing (NGS) for minimal residual disease (MRD) assessment to guide risk-stratified therapy. The regimen combines vincristine (a microtubule inhibitor), L-asparaginase (an enzyme that depletes asparagine), dexamethasone (a corticosteroid), and intrathecal administrations of cytarabine and methotrexate to target leukemic lymphoblasts through multiple cytotoxic mechanisms.

Other names

V-L-D-C-MVLDCMvincristine + L-asparaginase + dexamethasone + cytarabine + methotrexate